Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
Page(s) 16 - 19
Section M/S revues
DOI https://doi.org/10.1051/medsci/20052111s16
Publié en ligne 15 novembre 2005
  1. Futerman AH, Van Meer G. The cell biology of lysosomal storage disease. Nat Rev Mol Cell Biol 2004; 5 : 554–65. [Google Scholar]
  2. Raas-Rothschild A, Pankova-Kholmyansky I, Kacher Y, Futerman AH. Glycosphingolipidoses: beyond the enzymatic defect. Glycoconj J 2004 ; 21 : 295–304. [Google Scholar]
  3. de Duve C. Exploring cells with a centrifuge. Science 1975; 189 : 186–94. [Google Scholar]
  4. Ginzburg L, Kacher Y, Futerman AH. The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 2004; 5 : 417–31. [Google Scholar]
  5. Korkotian E, Schwarz A, Pelled D, et al. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem 1999; 274 : 21673–8. [Google Scholar]
  6. Pelled D, Shogomori H, Futerman AH. The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase. J Inherit Metab Dis 2000; 23 : 175–84. [Google Scholar]
  7. Lloyd-Evans E, Pelled D, Riebeling C, et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem 2003 ; 278 : 23594–9. [Google Scholar]
  8. Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky, E, Schiffmann R, Futerman AH. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis 2005; 18 : 83–8. [Google Scholar]
  9. Pelled D, Lloyd-Evans E, Riebeling C, et al. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J Biol Chem 2003; 278 : 29496–501. [Google Scholar]
  10. Lachmann RH. Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Investig Drugs 2003; 4 : 472–9. [Google Scholar]
  11. Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 1999; 96 : 6388–93. [Google Scholar]
  12. Ginzburg L, Futerman AH. Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J Neurochem 2005 (sous presse). [Google Scholar]
  13. Tessitore A, del P Martin M, Sano R, et al. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell 2004; 15 : 753–66. [Google Scholar]
  14. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Ann Rev Genom Hum Genet 2003; 4 : 403–36. [Google Scholar]
  15. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 2002; 3 : 954–66. [Google Scholar]
  16. Futerman AH, Sussman JL, Horowitz M, et al. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 2004; 25 : 147–51. [Google Scholar]
  17. Dvir H, Harel M, McCarthy AA, et al. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 2003; 4 : 704–9. [Google Scholar]
  18. Premkumar L, Sawkar AR, Boldin-Adamsky S, et al. X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J Biol Chem 2005; 280 : 23815–9. [Google Scholar]
  19. Fan JQ. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 2003; 24 : 355–60. [Google Scholar]
  20. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355 : 1481–5. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.